Danish study: women with Type 2 diabetes face 22% higher cancer incidence

A 27-year Danish registry study has linked Type 2 diabetes with higher cancer incidence, with the excess risk in women nearly double the excess risk recorded in men.

The finding matters first for Dubai clinics, insurers and medical directors because diabetes care can no longer be treated as a glucose-only pathway. The same patient cohort is also a cancer-screening cohort. In Dubai, the relevant regulator is the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain it is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, operators should check Ministry of Health and Prevention (MOHAP) guidance and local licensing rules.

What the study found

The National reported on 23 September 2026 that the Danish study assessed the country’s adult population between 1996 and 2022. Cancer cases were 12% higher in men with Type 2 diabetes than in men without the condition. In women with Type 2 diabetes, cancer cases were 22% higher than in women without the condition.

The excess risk was concentrated in obesity-related cancers. Between 2010 and 2022, these cancers were 45% higher in men with Type 2 diabetes and 30% higher in women with Type 2 diabetes than in people without diabetes, according to the same report. The cancers included colorectal cancer and postmenopausal breast cancer, two diseases with established screening pathways in the UAE.

“Prioritise cancer prevention and early detection as part of long-term diabetes care.” — Dr Tinne Laurberg, Steno Diabetes Centre, Aarhus University Hospital

The UAE exposure is large. The International Diabetes Federation lists 1,274,200 adults with diabetes in the UAE in 2024, equal to 20.7% adult prevalence. The National also cited 9,219 cancer cases in the UAE National Cancer Registry in 2024, up from 7,487 in 2023.

What Dubai and Abu Dhabi operators should change

For COOs, the immediate task is pathway design. Diabetes clinics should check whether patients aged 40 and above are being routed into breast and colorectal screening, rather than waiting for oncology referrals. DHA’s periodic screening guideline, effective 11 May 2024, recommends mammography every two years from age 40, colorectal screening from ages 40 to 75, colonoscopy every 10 years, or a faecal immunochemical test where appropriate.

For Abu Dhabi providers, DOH and Abu Dhabi Public Health Centre guidance says men and women aged 40 to 75 should consider colorectal screening. The IFHAS programme is available for Thiqa cardholders aged 18 to 75, with routine screening typically every three years or more often when clinically indicated. For colorectal cancer, Abu Dhabi Public Health Centre lists FIT once a year, colonoscopy once every 10 years, and a liquid biopsy option once every three years for eligible people.

• Dubai clinics: audit diabetic patients aged 40 and above against DHA screening intervals.
• Abu Dhabi clinics: verify IFHAS eligibility for Thiqa members and document referrals.
• Insurers: review whether diabetes case-management rules prompt covered cancer screening.
• Medical directors: update diabetes review templates to include cancer-screening status.

What hits the payer and patient

The financial signal is modest at screening level and larger at delayed-diagnosis level. Published UAE cash prices for standalone HbA1c tests range from AED 40 to AED 175 on Medifinder’s August 2026 comparison. Sukoon’s member benefit page lists a breast cancer screening offer at AED 499, subject to a valid health card and benefit rules. Colonoscopy costs and oncology work-ups vary by hospital, network, indication and pre-authorisation, so CFOs should use the DHA tariff file, DOH schedules and insurer portals rather than public package prices.

For patients, the practical question is eligibility. A woman with Type 2 diabetes who is 40 or older should ask her Dubai clinic whether her mammogram and colorectal screening are current under DHA guidance. An Abu Dhabi or Al Ain resident should ask whether Thiqa, Daman-administered plans, employer insurance or another policy covers the relevant IFHAS or provider pathway. In the northern emirates, patients should check MOHAP-linked guidance and their insurer’s network before booking.

The next operational test is whether diabetes registers and oncology screening registers can talk to each other. Clinics that can identify diabetic patients overdue for mammography, FIT or colonoscopy will have a measurable advantage in preventive care and payer reporting. To identify licensed oncology providers, readers can use the UAE Open Healthcare Directory and filter for oncology services across Dubai, Abu Dhabi and the northern emirates.